Peringatan Keamanan

The oral LD50 was 2500 mg/kg in rats. The dermal LD50 was 550 mg/kg in rabbits.L41735

Occasional cases of trientine overdose have been reported. A large overdose of 60 g of trientine hydrochloride resulted in nausea, vomiting, dizziness, mild acute kidney injury, mild hypophosphatemia, low serum zinc, and low serum copper: the patient recovered following intravenous hydration and supportive measures. There is no antidote for an acute overdose from trientine. Chronic use of trientine at dosages above the maximum recommended dosage has resulted in sideroblastic anemia.L41730

Triethylenetetramine

DB06824

small molecule approved investigational

Deskripsi

Triethylenetatramine (TETA), also known as trientine, is a potent and selective copper (II)-selective chelator. It is a structural analog of linear polyamine compounds, spermidine and spermine. TETA was first developed in Germany in 1861 and its chelating properties were first recognized in 1925.A19333 Initially approved by the FDA in 1985 as a second-line treatment for Wilson's disease,A19334 TETA is currently indicated to treat adults with stable Wilson’s disease who are de-coppered and tolerant to penicillamine.L41730

TETA has been investigated in clinical trials for the treatment of heart failure in patients with diabetes.A18804,A19332,A19333,A19334,A19335

Struktur Molekul 2D

Berat 146.2339
Wujud liquid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) The mean terminal half-life (t1/2) ranged from 13.8 to 16.5 hours.[L41730]
Volume Distribusi TETA is widely distributed in tissues, with relatively high concentrations measured in liver, heart, and kidney. It is prone to accumulation in certain tissues.[A19333] In healthy adult volunteers receiving oral capsules of TETA, the apparent volume of distribution of steady state was 645 L.[A18803]
Klirens (Clearance) In healthy adult volunteers receiving oral capsules of TETA, the oral total clearance was 69.5 L/h.[A18803]

Absorpsi

TETA is poorly absorbed from the gastrointestinal tract with an oral bioavailability ranging from 6% to 18%.A18803 TETA has the potential to chelate non-copper cations in mineral supplements and other oral drugs, resulting in altered drug absorption; thus, TETA should be administered at least one hour apart from these medications.L41730 The median Tmax ranges from 1.25 to 2 hours. Mean Cmax (± SD) of triethylenetetramine (TETA) was 2030 ± 981 ng/mL following oral administration of 900 mg TETA and 3430 ± 1480 ng/mL following administration of 1500 mg TETA. The systemic exposure (AUC) of TETA increased in a dose-proportional manner over the range of 900 mg to 1500 mg TETA. The mean AUCinf (± SD) was 9750 ± 4910 ngxh/mL at 900 mg and 17200 ± 9470 ngxh/mL at 1500 mg.L41730

Metabolisme

The majority of absorbed TETA is extensively metabolized into acetyl-metabolites.A18803 TETA undergoes acetylation mediated by diamine acetyltransferase, also known as spermidine/spermine N1-acetyltranferase,A18804,A19333 to form two major active metabolites, N1-acetyltriethylenetetramine (MAT) and N1,N10-diacetyltriethylenetetramine (DAT).L41730 The chelating activity of MAT is significantly lower than that of TETA.A19333

Rute Eliminasi

TETA and its metabolites, MAT and DAT, are mainly excreted in the urine.L41730 Approximately less than 1% of the administered dose is renally excreted as unchanged drug within the first six hours of dosing. About 8% of the dose is excreted as two major metabolites of TETA, MAT and DAT. Urinary excretion of metabolites occurs later than the excretion of the unchanged parent drug: it continues for 26 hours or longer.A18803

Interaksi Makanan

3 Data
  • 1. Avoid concomitant mineral supplements. Administer CUVRIOR at least 1 hour before or 2 hours after administration of other mineral supplements.
  • 2. Take at least 2 hours before or after iron supplements. Iron and triethylenetetramine inhibit each others absorption.
  • 3. Take on an empty stomach. Take CUVRIOR one hour before or two hours after eating a meal or at least one hour of separation from other drugs, milk, or food.

Interaksi Obat

804 Data
Zinc The serum concentration of Triethylenetetramine can be decreased when it is combined with Zinc.
Zinc trihydroxide The serum concentration of Triethylenetetramine can be decreased when it is combined with Zinc trihydroxide.
Zinc Substituted Heme C The serum concentration of Triethylenetetramine can be decreased when it is combined with Zinc Substituted Heme C.
Polaprezinc The serum concentration of Triethylenetetramine can be decreased when it is combined with Polaprezinc.
Zinc oxide The serum concentration of Triethylenetetramine can be decreased when it is combined with Zinc oxide.
Zinc sulfate The serum concentration of Triethylenetetramine can be decreased when it is combined with Zinc sulfate.
Zinc citrate The serum concentration of Triethylenetetramine can be decreased when it is combined with Zinc citrate.
Zinc picolinate The serum concentration of Triethylenetetramine can be decreased when it is combined with Zinc picolinate.
Zinc gluconate The serum concentration of Triethylenetetramine can be decreased when it is combined with Zinc gluconate.
Acetylcysteine zinc The serum concentration of Triethylenetetramine can be decreased when it is combined with Acetylcysteine zinc.
Zinc ascorbate The serum concentration of Triethylenetetramine can be decreased when it is combined with Zinc ascorbate.
Zinc acetate The serum concentration of Triethylenetetramine can be decreased when it is combined with Zinc acetate.
Zinc glycinate The serum concentration of Triethylenetetramine can be decreased when it is combined with Zinc glycinate.
Zinc chloride The serum concentration of Triethylenetetramine can be decreased when it is combined with Zinc chloride.
Zinc sulfate, unspecified form The serum concentration of Triethylenetetramine can be decreased when it is combined with Zinc sulfate, unspecified form.
Zinc cation The serum concentration of Triethylenetetramine can be decreased when it is combined with Zinc cation.
Calcium acetate Calcium acetate can cause a decrease in the absorption of Triethylenetetramine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Calcium glucoheptonate Calcium glucoheptonate can cause a decrease in the absorption of Triethylenetetramine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Calcium chloride Calcium chloride can cause a decrease in the absorption of Triethylenetetramine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Calcium Calcium can cause a decrease in the absorption of Triethylenetetramine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Calcium citrate Calcium citrate can cause a decrease in the absorption of Triethylenetetramine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Calcium gluconate Calcium gluconate can cause a decrease in the absorption of Triethylenetetramine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Calcium Phosphate Calcium Phosphate can cause a decrease in the absorption of Triethylenetetramine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Calcium lactate Calcium lactate can cause a decrease in the absorption of Triethylenetetramine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Calcium lactate gluconate Calcium lactate gluconate can cause a decrease in the absorption of Triethylenetetramine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Calcium pangamate Calcium pangamate can cause a decrease in the absorption of Triethylenetetramine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Calcium polycarbophil Calcium polycarbophil can cause a decrease in the absorption of Triethylenetetramine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Ethoxzolamide The excretion of Triethylenetetramine can be increased when combined with Ethoxzolamide.
Methazolamide The excretion of Triethylenetetramine can be increased when combined with Methazolamide.
Acetazolamide The excretion of Triethylenetetramine can be increased when combined with Acetazolamide.
Zonisamide The excretion of Triethylenetetramine can be increased when combined with Zonisamide.
Diclofenamide The excretion of Triethylenetetramine can be increased when combined with Diclofenamide.
Calcium carbonate Calcium carbonate can cause a decrease in the absorption of Triethylenetetramine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Magnesium oxide Magnesium oxide can cause a decrease in the absorption of Triethylenetetramine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Sodium bicarbonate Sodium bicarbonate can cause a decrease in the absorption of Triethylenetetramine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Aluminum hydroxide Aluminum hydroxide can cause a decrease in the absorption of Triethylenetetramine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Magaldrate Magaldrate can cause a decrease in the absorption of Triethylenetetramine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Magnesium hydroxide Magnesium hydroxide can cause a decrease in the absorption of Triethylenetetramine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Magnesium trisilicate Magnesium trisilicate can cause a decrease in the absorption of Triethylenetetramine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Magnesium carbonate Magnesium carbonate can cause a decrease in the absorption of Triethylenetetramine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Bismuth subnitrate Bismuth subnitrate can cause a decrease in the absorption of Triethylenetetramine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Magnesium silicate Magnesium silicate can cause a decrease in the absorption of Triethylenetetramine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Aluminium acetoacetate Aluminium acetoacetate can cause a decrease in the absorption of Triethylenetetramine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Hydrotalcite Hydrotalcite can cause a decrease in the absorption of Triethylenetetramine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Magnesium peroxide Magnesium peroxide can cause a decrease in the absorption of Triethylenetetramine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Almasilate Almasilate can cause a decrease in the absorption of Triethylenetetramine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Aluminium glycinate Aluminium glycinate can cause a decrease in the absorption of Triethylenetetramine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Aloglutamol Aloglutamol can cause a decrease in the absorption of Triethylenetetramine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Calcium silicate Calcium silicate can cause a decrease in the absorption of Triethylenetetramine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Aluminium phosphate Aluminium phosphate can cause a decrease in the absorption of Triethylenetetramine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Nitroprusside Triethylenetetramine can cause a decrease in the absorption of Nitroprusside resulting in a reduced serum concentration and potentially a decrease in efficacy.
Iron Dextran Triethylenetetramine can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.
Iron Triethylenetetramine can cause a decrease in the absorption of Iron resulting in a reduced serum concentration and potentially a decrease in efficacy.
Ferumoxytol Triethylenetetramine can cause a decrease in the absorption of Ferumoxytol resulting in a reduced serum concentration and potentially a decrease in efficacy.
Prussian blue Triethylenetetramine can cause a decrease in the absorption of Prussian blue resulting in a reduced serum concentration and potentially a decrease in efficacy.
Ferric carboxymaltose Triethylenetetramine can cause a decrease in the absorption of Ferric carboxymaltose resulting in a reduced serum concentration and potentially a decrease in efficacy.
Iron sucrose Triethylenetetramine can cause a decrease in the absorption of Iron sucrose resulting in a reduced serum concentration and potentially a decrease in efficacy.
Ferric pyrophosphate Triethylenetetramine can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Ferric ammonium citrate Triethylenetetramine can cause a decrease in the absorption of Ferric ammonium citrate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Ferumoxsil Triethylenetetramine can cause a decrease in the absorption of Ferumoxsil resulting in a reduced serum concentration and potentially a decrease in efficacy.
Ferumoxides Triethylenetetramine can cause a decrease in the absorption of Ferumoxides resulting in a reduced serum concentration and potentially a decrease in efficacy.
Ferric sulfate Triethylenetetramine can cause a decrease in the absorption of Ferric sulfate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Ferrous bisglycinate Triethylenetetramine can cause a decrease in the absorption of Ferrous bisglycinate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Gleptoferron Triethylenetetramine can cause a decrease in the absorption of Gleptoferron resulting in a reduced serum concentration and potentially a decrease in efficacy.
Ferric oxide Triethylenetetramine can cause a decrease in the absorption of Ferric oxide resulting in a reduced serum concentration and potentially a decrease in efficacy.
Perflubutane Triethylenetetramine can cause a decrease in the absorption of Perflubutane resulting in a reduced serum concentration and potentially a decrease in efficacy.
Ferrous sulfate anhydrous Triethylenetetramine can cause a decrease in the absorption of Ferrous sulfate anhydrous resulting in a reduced serum concentration and potentially a decrease in efficacy.
Sodium feredetate Triethylenetetramine can cause a decrease in the absorption of Sodium feredetate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Ferric hydroxide Triethylenetetramine can cause a decrease in the absorption of Ferric hydroxide resulting in a reduced serum concentration and potentially a decrease in efficacy.
Ferrous chloride Triethylenetetramine can cause a decrease in the absorption of Ferrous chloride resulting in a reduced serum concentration and potentially a decrease in efficacy.
Ferric cation Triethylenetetramine can cause a decrease in the absorption of Ferric cation resulting in a reduced serum concentration and potentially a decrease in efficacy.
Ferrous gluconate Triethylenetetramine can cause a decrease in the absorption of Ferrous gluconate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Ferrous succinate Triethylenetetramine can cause a decrease in the absorption of Ferrous succinate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Ferrous fumarate Triethylenetetramine can cause a decrease in the absorption of Ferrous fumarate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Tetraferric tricitrate decahydrate Triethylenetetramine can cause a decrease in the absorption of Tetraferric tricitrate decahydrate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Ferric oxyhydroxide Triethylenetetramine can cause a decrease in the absorption of Ferric oxyhydroxide resulting in a reduced serum concentration and potentially a decrease in efficacy.
Ferric maltol Triethylenetetramine can cause a decrease in the absorption of Ferric maltol resulting in a reduced serum concentration and potentially a decrease in efficacy.
Iron isomaltoside 1000 Triethylenetetramine can cause a decrease in the absorption of Iron isomaltoside 1000 resulting in a reduced serum concentration and potentially a decrease in efficacy.
Iron polymaltose Triethylenetetramine can cause a decrease in the absorption of Iron polymaltose resulting in a reduced serum concentration and potentially a decrease in efficacy.
Technetium Tc-99m oxidronate Triethylenetetramine may decrease effectiveness of Technetium Tc-99m oxidronate as a diagnostic agent.
Cyclosporine Cyclosporine may decrease the excretion rate of Triethylenetetramine which could result in a higher serum level.
Icosapent Icosapent may decrease the excretion rate of Triethylenetetramine which could result in a higher serum level.
Cefotiam Cefotiam may decrease the excretion rate of Triethylenetetramine which could result in a higher serum level.
Mesalazine Mesalazine may decrease the excretion rate of Triethylenetetramine which could result in a higher serum level.
Cefmenoxime Cefmenoxime may decrease the excretion rate of Triethylenetetramine which could result in a higher serum level.
Cefmetazole Cefmetazole may decrease the excretion rate of Triethylenetetramine which could result in a higher serum level.
Pamidronic acid Pamidronic acid may decrease the excretion rate of Triethylenetetramine which could result in a higher serum level.
Tenofovir disoproxil Tenofovir disoproxil may decrease the excretion rate of Triethylenetetramine which could result in a higher serum level.
Indomethacin Indomethacin may decrease the excretion rate of Triethylenetetramine which could result in a higher serum level.
Cidofovir Cidofovir may decrease the excretion rate of Triethylenetetramine which could result in a higher serum level.
Cefpiramide Cefpiramide may decrease the excretion rate of Triethylenetetramine which could result in a higher serum level.
Ceftazidime Ceftazidime may decrease the excretion rate of Triethylenetetramine which could result in a higher serum level.
Loracarbef Loracarbef may decrease the excretion rate of Triethylenetetramine which could result in a higher serum level.
Cefalotin Cefalotin may decrease the excretion rate of Triethylenetetramine which could result in a higher serum level.
Nabumetone Nabumetone may decrease the excretion rate of Triethylenetetramine which could result in a higher serum level.
Ketorolac Ketorolac may decrease the excretion rate of Triethylenetetramine which could result in a higher serum level.
Tenoxicam Tenoxicam may decrease the excretion rate of Triethylenetetramine which could result in a higher serum level.
Celecoxib Celecoxib may decrease the excretion rate of Triethylenetetramine which could result in a higher serum level.
Cefotaxime Cefotaxime may decrease the excretion rate of Triethylenetetramine which could result in a higher serum level.
Tolmetin Tolmetin may decrease the excretion rate of Triethylenetetramine which could result in a higher serum level.

Target Protein

Carbonic anhydrase 14 CA14

Referensi & Sumber

Artikel (PubMed)
  • PMID: 19602718
    Cho HY, Blum RA, Sunderland T, Cooper GJ, Jusko WJ: Pharmacokinetic and pharmacodynamic modeling of a copper-selective chelator (TETA) in healthy adults. J Clin Pharmacol. 2009 Aug;49(8):916-28. doi: 10.1177/0091270009337939.
  • PMID: 20145262
    Lu J, Poppitt SD, Othman AA, Sunderland T, Ruggiero K, Willett MS, Diamond LE, Garcia WD, Roesch BG, Cooper GJ: Pharmacokinetics, pharmacodynamics, and metabolism of triethylenetetramine in healthy human participants: an open-label trial. J Clin Pharmacol. 2010 Jun;50(6):647-58. doi: 10.1177/0091270009349379. Epub 2010 Feb 9.
  • PMID: 17108057
    Lu J, Chan YK, Gamble GD, Poppitt SD, Othman AA, Cooper GJ: Triethylenetetramine and metabolites: levels in relation to copper and zinc excretion in urine of healthy volunteers and type 2 diabetic patients. Drug Metab Dispos. 2007 Feb;35(2):221-7. Epub 2006 Nov 15.
  • PMID: 20660601
    Lu J: Triethylenetetramine pharmacology and its clinical applications. Mol Cancer Ther. 2010 Sep;9(9):2458-67. doi: 10.1158/1535-7163.MCT-10-0523. Epub 2010 Jul 26.
  • PMID: 21770477
    Cooper GJ: Therapeutic potential of copper chelation with triethylenetetramine in managing diabetes mellitus and Alzheimer's disease. Drugs. 2011 Jul 9;71(10):1281-320. doi: 10.2165/11591370-000000000-00000.
  • PMID: 20221822
    Lu J, Gong D, Choong SY, Xu H, Chan YK, Chen X, Fitzpatrick S, Glyn-Jones S, Zhang S, Nakamura T, Ruggiero K, Obolonkin V, Poppitt SD, Phillips AR, Cooper GJ: Copper(II)-selective chelation improves function and antioxidant defences in cardiovascular tissues of rats as a model of diabetes: comparisons between triethylenetetramine and three less copper-selective transition-metal-targeted treatments. Diabetologia. 2010 Jun;53(6):1217-26. doi: 10.1007/s00125-010-1698-8. Epub 2010 Mar 11.
  • PMID: 22340672
    Authors unspecified: EASL Clinical Practice Guidelines: Wilson's disease. J Hepatol. 2012 Mar;56(3):671-85. doi: 10.1016/j.jhep.2011.11.007.

Contoh Produk & Brand

Produk: 28 • International brands: 0
Produk
  • Cufence
    Capsule • 200 mg • Oral • EU • Approved
  • Cufence
    Capsule • 100 mg • Oral • EU • Approved
  • Cuprior
    Tablet, film coated • 150 mg • Oral • EU • Approved
  • Cuprior
    Tablet, film coated • 150 mg • Oral • EU • Approved
  • Cuvrior
    Tablet, film coated • 300 mg/1 • Oral • US • Approved
  • Mar-trientine
    Capsule • 250 mg • Oral • Canada • Generic • Approved
  • Syprine
    Capsule • 250 mg/1 • Oral • US • Approved
  • Syprine
    Capsule • 250 mg/1 • Oral • US • Approved
Menampilkan 8 dari 28 produk.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul